Medication Abortion: New Litigation May Affect Access (CRS Report for Congress)
| Release Date |
Revised Aug. 28, 2023 |
| Report Number |
LSB10919 |
| Report Type |
Legal Sidebar |
| Authors |
Jennifer A. Staman |
| Source Agency |
Congressional Research Service |
| Older Revisions |
-
Premium Revised April 24, 2023 (4 pages, $24.95)
add
-
Premium Revised April 19, 2023 (4 pages, $24.95)
add
-
Premium Revised April 14, 2023 (4 pages, $24.95)
add
-
Premium Feb. 14, 2023 (3 pages, $24.95)
add
|
Summary:
The Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization has spurred significant
debate over federal and state regulation of medication abortion—a pregnancy termination method
involving the use of prescription drugs. Recent attention has centered on how these drugs may provide
broader access to elective abortion, particularly for those residing in areas with few or no abortion
providers. The scope of federal and state authority to regulate medication abortion is the subject of a
number of high-profile lawsuits that raise questions about the future availability of these products. This
Legal Sidebar explores federal and state regulation of medication abortion drugs, ongoing litigation
concerning medication abortion access, and selected legal considerations for Congress.
